The controlling shareholder of Guanhao Biology (300238.SZ) pledges 14.65 million shares
Guanhao Biotech (300238.SZ) announced that the company recently received a notice from Guangdong Zhiguang Biotechnology Co., Ltd. (“Guangdong Zhiguang”), the controlling shareholder of the company, and learned that it will hold 14.65 million shares of the company (accounting for 5.52% of the company's total share capital) to register the pledge registration business.
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutica
Medical beauty stocks fell collectively. Among them, Jiangsu Wuzhong fell to a standstill, Aimeike fell more than 9%, Jingfeng Pharmaceutical fell more than 5%, Huadong Pharmaceutical, Betaini, and Guanhao Biotech fell more than 4%, and Teyi Pharmaceutical, Shuyu Pingmin, Changshan Pharmaceutical, and Dian Diagnosis fell more than 3%.
Guanhao Biology (300238.SZ): As of March 20, 2024, the total number of shareholders of the company was 31,042
Gelonghui March 21丨Guanhao Biotech (300238.SZ) said on the investor interactive platform that as of March 20, 2024, the total number of shareholders of the company was 31,042.
Guan Hao Biology (300238.SZ): No plans to participate in the brain-computer interface conference
Gelonghui March 12 丨 Guanhao Biology (300238.SZ) said on the investor interactive platform that the company has no plans to participate in the brain-computer interface conference yet.
Guanhao Biology (300238) 2023 Report Review: Benvermode is growing rapidly and new biomaterial products are being released rapidly
Incident: The company released its 2023 annual report, achieving operating income of 400 million yuan (+7.1%); net profit attributable to shareholders of listed companies was 0.3 billion yuan. Achieved revenue of 100 million yuan (+14.3%) in the fourth quarter of 2023;
Guanhao Biotech (300238.SZ): 2023 net profit of 31.058 million yuan reversed year-on-year losses
Gelonghui March 5 | Guanhao Biotech (300238.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 404 million yuan, an increase of 7.13% over the previous year; net profit attributable to shareholders of listed companies was 31.058 million yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 305.554 million yuan; and basic earnings per share were 0.12 yuan.
Express News | Guan Hao Biology: Received a warning letter from the Guangdong Securities Regulatory Bureau
Guanhao Biology (300238.SZ): Expected net profit of 28 million yuan to 33 million yuan in 2023 to reverse the year-on-year loss
On January 25, Gelonghui | Guanhao Biotech (300238.SZ) announced that it expects net profit of 28 million yuan to 33 million yuan in 2023, reversing losses year-on-year, and deducting non-net profit of 23.85 million yuan to 28.85 million yuan, reversing year-on-year losses. During the reporting period, the company actively developed the market. The company's revenue for some membrane products, benvilimod cream, and cell technology services all increased compared to the same period last year. The company estimates that the impact of non-recurring profit and loss in 2023 on net profit attributable to shareholders of listed companies is approximately RMB 4.15 million.
Guanhao Biology (300238.SZ): Appoints Zhang Yongming as the company's general manager
Gelonghui, January 14, 丨 Guanhao Biology (300238.SZ) issued an announcement. The board of directors recently received the resignation report submitted by Wang Xinzhi. Wang Xinzhi applied to resign as general manager of the company due to his personal age. After his resignation, Wang Xinzhi will continue to serve as Vice Chairman of the Company's 6th Board of Directors and a member of the Strategy Committee. Wang Xinzhi's resignation report took effect on the day it was delivered to the board of directors, and his resignation will not adversely affect the company's daily operations. The company held the fifth meeting of the sixth board of directors on January 12, 2024 to review and pass the “Proposal on the Appointment of the Company's General Manager”. The board of directors proposed by the chairman
Guanhao Biology (300238.SZ): As of January 10, 2024, the total number of shareholders of the company was 30,725
Gelonghui January 12 | Guanhao Biotech (300238.SZ) said on the investor interactive platform that as of January 10, 2024, the total number of shareholders of the company was 30,725.
Guanhao Biotech (300238.SZ): Controlling shareholder dissolves 5.53% of company shares
Guanhao Biotech (300238.SZ) announced that Guangdong Zhiguang Biotechnology Co., Ltd., the controlling shareholder of the company (hereinafter referred to as...
Guan Hao Biology (300238.SZ): No research related to gene editing has been involved
On November 20, Gelonghui, Guanhao Biotech (300238.SZ) stated on the investor interactive platform that the company has not yet been involved in research related to gene editing.
Guanhao Biology (300238.SZ): Products such as biotype dura (dorsal) membrane patches, type B dura patches, etc. are mainly used in neurosurgery
Gelonghui November 14|Guanhao Biology (300238.SZ) stated on the investor interactive platform that the company's products, such as biotype hard brain (spine) patch and type B durum patch, are mainly used in neurosurgery.
Guanhao Biology (300238.SZ): The product, Verimod, can treat inflammatory and autoimmune diseases, such as psoriasis, atopic dermatitis, etc.
Gelonghui November 14|Guanhao Biotech (300238.SZ) stated on the investor interactive platform that the company's main product in the pharmaceutical field, benvermod, can treat inflammatory and autoimmune diseases, such as psoriasis and atopic dermatitis.
Guanhao Biotech (300238.SZ): As of November 10, 2023, the total number of shareholders in the company is 33213
Gelonghui November 14|Guanhao Biotech (300238.SZ) stated on the investor interactive platform that as of November 10, 2023, the total number of shareholders in the company was 3,3213.
Guanhao Biology (300238.SZ): The biological artificial liver project carried out is currently in the scientific research and clinical research stage
Gelonghui November 9: Some investors asked Guanhao Biotech (300238.SZ) on the investor interactive platform, “How is the company's biotype artificial liver research and development progressing?” The company replied that the biological artificial liver project carried out by the company is currently in the scientific research and clinical research stage.
Guanhao Biology (300238): Benvermode is growing rapidly and contributing to new biofilm products and cell services
Event: The company released its three-quarter report for 2023, achieving operating income of 310 million yuan (+5.1%); net profit attributable to shareholders of listed companies was 0.4 billion yuan (+117.8%), net profit attributable to shareholders of listed companies after deduction, net profit attributable to shareholders of listed companies
[Instant Analysis of BT Financial Report] Guan Hao Biotech 2023 Third Quarter Report: Debt Ratio Declines, Net Profit Reverses Losses, and Performance Improves Steady
Announcement time of this financial report: 2023-10-24 16:57:48 Guanhao Biotech (stock code: 300238) is a high-tech enterprise dedicated to innovation and development in the biomedical industry. Since its establishment, the company has been focusing on original technology in the field of biomedicine, and has laid out in the fields of biomaterials, pharmaceuticals, cells and advanced medical technology. The company's self-developed regenerative medicine materials and new drugs, as well as cell and stem cell research and application platforms, have achieved remarkable results in their respective fields. In terms of assets and liabilities, Guan Hao Biotech's 2023 three-quarter report shows that the company's total assets
Guan Hao Biotech (300238.SZ): Net profit of 41.27 million yuan for the first three quarters
GLONGHUI, Oct. 24, 丨 Guan Hao Biotech (300238.SZ) announced its third quarter report. Operating revenue was 309 million yuan, up 5.09% year on year, net profit of 41.27 million yuan, net profit of 41.27 million yuan, net profit of 3.895 million yuan, and basic earnings per share of 0.16 yuan.
Guan Hao Biology (300238.SZ): There are currently no studies related to brain-computer interfaces
Glonghui September 22丨Guan Hao Biotech (300238.SZ) said on the investor interactive platform that the company has no research on brain-computer interfaces yet. The company's main products involved in neurosurgery include biotype scleroid (spinal) membrane patches, type B dural meningeal patches, etc.
No Data